EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy

David R Gandara iD, Mahmut Gümüş iD, Saadettin Kilickap iD, Ahmet Sezer, Igor Bondarenko, Mustafa Özgüroğlu, Miranda Gogishvili, Eric Yan, Xue Jia, Eric Kim, Frank Seebach, Ruben G W Quek

Cancer · 15.03.2026 · 132 (6)

DOI: 10.1002/cncr.70339 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 11.03.2026. Verfasst von David R Gandara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Medicine, University of California-Davis Comprehensive Cancer Center, Sacramento, California, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Regeneron Pharmaceuticals, Inc., Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patient‐reported outcomes (PROs) for cemiplimab monotherapy versus chemotherapy from the EMPOWER‐Lung 1 phase 3 clinical trial (ClinicalTrials.gov identifier NCT03088540) in patients who had advanced non‐small cell lung cancer with programmed cell death‐ligand 1 expression ≥50% were previously reported.

Methods

This review article characterizes PRO findings for cemiplimab monotherapy versus chemotherapy overall and in prespecified subgroups of patients from the EMPOWER‐Lung 1 clinical trial. Patients were randomly assigned 1:1 to receive either cemiplimab 350 mg every 3 weeks or platinum‐doublet chemotherapy, and multiple PROs, including the European Organization for Research and Treatment of Cancer Quality of Life–Core 30 questionnaire, were administered in the EMPOWER‐Lung 1 trial. PRO analyses using mixed model for repeated measures analysis to estimate least‐squares mean changes in PRO scores from baseline and Cox proportional hazards models for the time to deterioration using a 10‐point threshold have been reported and are summarized herein.

Results

Generally, the mixed model for repeated measures analysis of global health status/quality of life (GHS/QoL) significantly favored cemiplimab versus chemotherapy in the overall study population and in prespecified subgroup populations. Statistically significant differences in the overall change from baseline in GHS/QoL favoring cemiplimab versus chemotherapy were observed overall and in multiple subgroups, including patients who had brain metastasis ( p = .0110), an Eastern Cooperative Oncology Group performance status of 1 ( p = .0017), squamous ( p = .0247) and nonsquamous ( p = .0073) histology, and patients aged 65 years and older ( p = .0069). Statistically significant delays in the time to deterioration favoring cemiplimab were observed in GHS/QoL for the subgroup with programmed cell death‐ligand 1 expression ≥90% ( p = .0152) and the subgroup younger than 65 years ( p = .0195).

Conclusions

Collectively, the current data support the GHS/QoL benefit of first‐line cemiplimab monotherapy versus chemotherapy overall and in multiple subpopulations of patients with programmed cell death‐ligand 1 expression ≥50% advanced non‐small cell lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsPatient Reported Outcome MeasuresAgedFemaleHumansMaleMiddle AgedB7-H1 AntigenQuality of LifeRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

advanced non‐small cell lung cancercemiplimabimmunotherapypatient‐reported outcomesprogrammed cell death‐ligand 1 (PD‐L1)

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 Antigen

Autor:innen und Institutionen

  • Division of Hematology and Oncology, Department of Medicine, University of California-Davis Comprehensive Cancer Center, Sacramento, California, USA.
  • Department of Medical Oncology, School of Medicine, Istanbul Medeniyet University, Istanbul, Turkey.
  • Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Turkey.
  • Department of Medical Oncology, Başkent University, Adana, Turkey.
  • Department of Oncology and Medical Radiology, Dnipropetrovsk Medical University, Dnipro, Ukraine.
  • Cerrahpaşa Medical Faculty, Istanbul University-Cerrahpaşa, Istanbul, Turkey.

ORCID-Profile: David R Gandara, Mahmut Gümüş, Saadettin Kilickap

Förderung

  • Regeneron Pharmaceuticals, Inc.
  • Sanofi

Zitieren

APA

Gandara, D. R., Gümüş, M., Kilickap, S., Sezer, A., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Yan, E., Jia, X., Kim, E., Seebach, F., & Quek, R. G. W. (2026). Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy. Cancer, 132(6). https://doi.org/10.1002/cncr.70339

Vancouver

Gandara DR, Gümüş M, Kilickap S, Sezer A, Bondarenko I, Özgüroğlu M, et al. Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy. Cancer. 2026;132(6). doi:10.1002/cncr.70339

BibTeX
@article{Gandara2026,
  author = {Gandara, David R and Gümüş, Mahmut and Kilickap, Saadettin and Sezer, Ahmet and Bondarenko, Igor and Özgüroğlu, Mustafa and Gogishvili, Miranda and Yan, Eric and Jia, Xue and Kim, Eric and Seebach, Frank and Quek, Ruben G W},
  title = {Review of patient‐reported outcomes in EMPOWER‐Lung 1 in patients with advanced non‐small cell lung cancer treated with cemiplimab versus chemotherapy},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {6},
  doi = {10.1002/cncr.70339}
}
Kostenlos starten →